Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Convertible Debt (2016 - 2025)

Coherus Oncology's Convertible Debt history spans 10 years, with the latest figure at $228.6 million for Q1 2025.

  • For Q1 2025, Convertible Debt rose 0.59% year-over-year to $228.6 million; the TTM value through Mar 2025 reached $228.6 million, up 0.59%, while the annual FY2024 figure was $228.2 million, 0.59% up from the prior year.
  • Convertible Debt for Q1 2025 was $228.6 million at Coherus Oncology, roughly flat from $228.2 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $332.8 million in Q4 2021 and bottomed at $223.3 million in Q1 2021.
  • The 5-year median for Convertible Debt is $226.2 million (2023), against an average of $232.3 million.
  • The largest annual shift saw Convertible Debt skyrocketed 183.19% in 2021 before it tumbled 32.21% in 2022.
  • A 5-year view of Convertible Debt shows it stood at $332.8 million in 2021, then crashed by 32.21% to $225.6 million in 2022, then grew by 0.58% to $226.9 million in 2023, then rose by 0.59% to $228.2 million in 2024, then increased by 0.15% to $228.6 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Convertible Debt are $228.6 million (Q1 2025), $228.2 million (Q4 2024), and $227.9 million (Q3 2024).